Point72 Asset Management
AVTX icon

Point72 Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Point72 Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.7M Buy
916,142
+288,640
+46% +$4.51M 0.02% 1032
2025
Q4 		$11.4M Sell
627,502
-426,481
-40% -$7.2M 0.01% 1278
2025
Q3 		$13.4M Buy
+1,053,983
New +$9.06M 0.02% 689
2023
Q2 		– Sell
-4,586
Closed -$1.93M – 2171
2023
Q1 		$1.93M Buy
4,586
+2,500
+120% +$1.97M 0.01% 986
2022
Q4 		$2.52M Hold
2,086
– – 0.01% 894
2022
Q3 		$1.66M Hold
2,086
– – 0.01% 962
2022
Q2 		$3M Hold
2,086
– – 0.01% 838
2022
Q1 		$4.36M Hold
2,086
– – 0.02% 738
2021
Q4 		$10.2M Hold
2,086
– – 0.04% 505
2021
Q3 		$13.1M Buy
2,086
+1,633
+360% +$13.2M 0.06% 424
2021
Q2 		$4.27M Sell
453
-398
-47% -$3.33M 0.02% 631
2021
Q1 		$7.4M Buy
+851
New +$8.04M 0.03% 497

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management's AVTX Position: Q1 2026 in Review

Point72 Asset Management increased its Avalo Therapeutics (AVTX) stake by 46% in Q1 2026, buying an estimated $4.51M and bringing the position to 916,142 shares worth $13.7M. The position accounts for 0.02% of the portfolio, ranked #1032.

Point72 Asset Management first reported a position in AVTX in Q1 2021 and has held it in 12 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Point72 Asset Management held 916,142 shares of Avalo Therapeutics worth $13.7M as of Q1 2026.
  • Point72 Asset Management bought 288,640 Avalo Therapeutics shares in Q1 2026, an estimated $4.51M.
  • Avalo Therapeutics made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #1032 holding.
  • Point72 Asset Management first reported a position in Avalo Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.